STAMFORD, CT–(BUSINESS WIRE<\/a>)– \nPhilip Morris International Inc.\u2019s (NYSE: PM) Chief Financial Officer, Emmanuel Babeau, will address investors today at the Deutsche Bank Global Consumer Conference in Paris.<\/p>\n \nThe session will be webcast live in listen-only mode, beginning at approximately 9:15 a.m. CEST (3:15 a.m. ET), at www.pmi.com\/2023deutschebank<\/a>, and on the PMI Investor Relations Mobile Application (available for download at www.pmi.com\/irapp<\/a>). Presentation slides will also be available on the same site and the App. An archived copy of the webcast will be available until 5:00 p.m. ET on Friday, July 7, 2023, also at www.pmi.com\/2023deutschebank<\/a>.<\/p>\n “We expect strong second-quarter performance, including total shipment volume growth driven by our smoke-free portfolio,”<\/i> said Emmanuel Babeau, Chief Financial Officer. \u201cToday, we are reaffirming our 2023 full-year EPS forecast, which is underpinned by the excellent outlook for IQOS and ZYN.\u201d<\/i><\/p>\n 2023 Full-Year Forecast<\/b><\/p>\n \nPMI reaffirms its 2023 full-year reported diluted EPS forecast, announced on April 20, 2023, of $5.88 to $6.00, at then-prevailing exchange rates. Excluding a total 2023 adjustment of $0.22 per share and an unfavorable currency impact, at then-prevailing exchange rates, of $0.30 per share, this forecast represents a projected currency-neutral increase of 7% to 9% versus adjusted diluted EPS of $5.98 in 2022, as outlined in the below table.<\/p>\n
\nRegulatory News:<\/p>\n
| \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| \n \n\u00a0<\/p>\n<\/td>\n | \n Full-Year<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n 2023 \n\u00a0<\/p>\n<\/td>\n 2022<\/b><\/p>\n<\/td>\n Growth<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Reported Diluted EPS<\/b><\/p>\n<\/td>\n $5.88<\/b><\/p>\n<\/td>\n \u00a0–\u00a0<\/b><\/p>\n<\/td>\n $6.00<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n $5.81<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Adjustments<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nAsset impairment and exit costs<\/p>\n<\/td>\n \n0.06<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nAmortization and impairment of intangibles<\/p>\n<\/td>\n \n0.16<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0.15<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nTermination of distribution arrangement in Middle East<\/p>\n<\/td>\n \n0.04<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nCharges related to the war in Ukraine<\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0.08<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nCosts associated with Swedish Match AB offer<\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0.06<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nSwedish Match AB acquisition accounting related item<\/p>\n<\/td>\n \n0.01<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n0.06<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nTax benefit associated with Swedish Match AB financing<\/p>\n<\/td>\n \n(0.05)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(0.13)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nFair value adj. for equity security investments<\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(0.02)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nTax Items<\/p>\n<\/td>\n \n–<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n(0.03)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Total Adjustments<\/b><\/p>\n<\/td>\n 0.22<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n 0.17<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Adjusted Diluted EPS<\/b><\/p>\n<\/td>\n $6.10<\/b><\/p>\n<\/td>\n –\u00a0<\/b><\/p>\n<\/td>\n $6.22<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n $5.98<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \nLess Currency (a)<\/sup><\/p>\n<\/td>\n \n(0.30)<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n Adjusted Diluted EPS, excluding currency<\/b><\/p>\n<\/td>\n $6.40<\/b><\/p>\n<\/td>\n –\u00a0<\/b><\/p>\n<\/td>\n $6.52<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n $5.98<\/b><\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n 7%<\/b><\/p>\n<\/td>\n –\u00a0<\/b><\/p>\n<\/td>\n 9%<\/b><\/p>\n<\/td>\n<\/tr>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n \n(a) At then-prevailing exchange rates used for the company\u2019s April 20th<\/sup> forecast<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \nThe assumptions underlying this forecast remain unchanged versus those communicated by PMI in its earnings release of April 20th<\/sup>, with the exception of the following assumptions specific to the second quarter:<\/p>\n \nFactors described in the Forward-Looking and Cautionary Statements section of this release represent continuing risks to these projections.<\/p>\n Forward-Looking & Cautionary Statements<\/b><\/p>\n \nThe presentation, related discussion and this press release contain projections of future results and goals and other forward-looking statements, including statements regarding expected financial or operational performance; capital allocation plans; investment strategies; regulatory outcomes; market expectations; and business plans and strategies. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. In the event that risks or uncertainties materialize, or underlying assumptions prove inaccurate, actual results could vary materially from those contained in such forward-looking statements. Pursuant to the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995, PMI is identifying important factors that, individually or in the aggregate, could cause actual results and outcomes to differ materially from those contained in any forward-looking statements made by PMI.<\/p>\n \nPMI’s business risks include: excise tax increases and discriminatory tax structures; increasing marketing and regulatory restrictions that could reduce our competitiveness, eliminate our ability to communicate with adult consumers, or ban certain of our products in certain markets or countries; health concerns relating to the use of tobacco and other nicotine-containing products and exposure to environmental tobacco smoke; litigation related to tobacco use and intellectual property; intense competition; the effects of global and individual country economic, regulatory and political developments, natural disasters and conflicts; the impact and consequences of Russia’s invasion of Ukraine; changes in adult smoker behavior; the impact of COVID-19 on PMI’s business; lost revenues as a result of counterfeiting, contraband and cross-border purchases; governmental investigations; unfavorable currency exchange rates and currency devaluations, and limitations on the ability to repatriate funds; adverse changes in applicable corporate tax laws; adverse changes in the cost, availability, and quality of tobacco and other agricultural products and raw materials, as well as components and materials for our electronic devices; and the integrity of its information systems and effectiveness of its data privacy policies. PMI’s future profitability may also be adversely affected should it be unsuccessful in its attempts to produce and commercialize reduced-risk products or if regulation or taxation do not differentiate between such products and cigarettes; if it is unable to successfully introduce new products, promote brand equity, enter new markets or improve its margins through increased prices and productivity gains; if it is unable to expand its brand portfolio internally or through acquisitions and the development of strategic business relationships; if it is unable to attract and retain the best global talent, including women or diverse candidates; or if it is unable to successfully integrate and realize the expected benefits from recent transactions and acquisitions. Future results are also subject to the lower predictability of our reduced-risk product category’s performance.<\/p>\n \nPMI is further subject to other risks detailed from time to time in its publicly filed documents, including PMI’s Annual Report on Form 10-K for the year ended December 31, 2022, and the Form 10-Q for the first quarter ended March 31, 2023. PMI cautions that the foregoing list of important factors is not a complete discussion of all potential risks and uncertainties. PMI does not undertake to update any forward-looking statement that it may make from time to time, except in the normal course of its public disclosure obligations.<\/p>\n Philip Morris International: Delivering a Smoke-Free Future<\/b><\/p>\n \nPhilip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company\u2019s current product portfolio primarily consists of cigarettes and smoke-free products. Since 2008, PMI has invested more than USD 10.5 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In November 2022, PMI acquired Swedish Match \u2013 a leader in oral nicotine delivery \u2013 creating a global smoke-free champion led by the companies\u2019 IQOS<\/i> and ZYN<\/i> brands. The U.S. Food and Drug Administration (FDA) has authorized versions of PMI\u2019s IQOS<\/i> Platform 1 devices and consumables and Swedish Match\u2019s General<\/i> snus as Modified Risk Tobacco Products (MRTPs). As of March 31, 2023, PMI’s smoke-free products were available for sale in 78 markets, and PMI estimates that approximately 18.5 million adults around the world had already switched to IQOS<\/i> and stopped smoking. Smoke-free products accounted for approximately 35% of PMI\u2019s total 2023 first-quarter net revenues. With a strong foundation and significant expertise in life sciences, PMI announced in February 2021 its ambition to expand into wellness and healthcare areas and, through its Vectura Fertin Pharma business, aims to enhance life through the delivery of seamless health experiences. For more information, please visit www.pmi.com<\/a> and www.pmiscience.com<\/a>.<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230605005843\/en\/<\/a><\/span><\/p>\n \nInvestor Relations: \nMedia: David Fraser KEYWORDS:<\/b> United States North America Connecticut<\/p>\n INDUSTRY KEYWORDS:<\/b> Tobacco Retail Professional Services Finance<\/p>\n |
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20230605005843\/en\/1056493\/3\/PMI_global_V_Blue_HIRES.jpg\")
<\/td>\n<\/tr>\n